{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:58:49Z","timestamp":1789041529925,"version":"build-2803163510"},"reference-count":47,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autologous stem cell transplantation (ASCT) can be curative for patients with relapsed\/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 monoclonal antibodies (mAbs) can sensitize patients to subsequent chemotherapy, we hypothesized that anti-PD-1 therapy before ASCT would result in acceptable outcomes among high-risk patients who progressed on or responded insufficiently to \u22651 salvage regimen, including chemorefractory patients who are traditionally considered poor ASCT candidates. We retrospectively identified 78 HL patients who underwent ASCT after receiving an anti-PD-1 mAb (alone or in combination) as third-line or later therapy across 22 centers. Chemorefractory disease was common, including 42 patients (54%) refractory to \u22652 consecutive systemic therapies immediately before anti-PD-1 treatment. Fifty-eight (74%) patients underwent ASCT after anti-PD-1 treatment, while 20 patients (26%) received additional therapy after PD-1 blockade and before ASCT. Patients received a median of 4 systemic therapies (range, 3-7) before ASCT, and 31 patients (41%) had a positive pre-ASCT positron emission tomography (PET) result. After a median post-ASCT follow-up of 19.6 months, the 18-month progression-free survival (PFS) and overall survival were 81% (95% CI, 69-89) and 96% (95% confidence interval [CI], 87-99), respectively. Favorable outcomes were observed for patients who were refractory to 2 consecutive therapies immediately before PD-1 blockade (18-month PFS, 78%), had a positive pre-ASCT PET (18-month PFS, 75%), or received \u22654 systemic therapies before ASCT (18-month PFS, 73%), while PD-1 nonresponders had inferior outcomes (18-month PFS, 51%). In this high-risk cohort, ASCT after anti-PD-1 therapy was associated with excellent outcomes, even among heavily pretreated, previously chemorefractory patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003556","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T11:35:17Z","timestamp":1615548917000},"page":"1648-1659","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma"],"prefix":"10.1182","volume":"5","author":[{"given":"Reid W.","family":"Merryman","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancies and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-5288","authenticated-orcid":false,"given":"Robert A.","family":"Redd","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Chavez","sequence":"additional","affiliation":[{"name":"Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6034-8939","authenticated-orcid":false,"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Darrah","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA;"},{"name":"Cedars-Sinai Medical Center, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uttam","family":"Rao","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Byrne","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1829","authenticated-orcid":false,"given":"David A.","family":"Bond","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University Hospital, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami J.","family":"Maddocks","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University Hospital, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Spinner","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatcher J.","family":"Ballard","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag K.","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-8844","authenticated-orcid":false,"given":"Dipenkumar","family":"Modi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Institute\/Wayne State University, Detroit, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishnan","family":"Ramchandren","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Tennessee School of Medicine, Knoxville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0054-9362","authenticated-orcid":false,"given":"Jason","family":"Romancik","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University\u2013Winship Cancer Institute, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-6481","authenticated-orcid":false,"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University\u2013Winship Cancer Institute, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Program, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Program, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V.","family":"Serritella","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Kline","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ansell","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Nathan","sequence":"additional","affiliation":[{"name":"Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Rahimian","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7251-8082","authenticated-orcid":false,"given":"Robin M.","family":"Joyce","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8884-3085","authenticated-orcid":false,"given":"Mansi","family":"Shah","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"David","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5674-6408","authenticated-orcid":false,"given":"Steven","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne W.","family":"Beaven","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of North Carolina, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Habib","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Nakhoda","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0894","authenticated-orcid":false,"given":"Ryan C.","family":"Lynch","sequence":"additional","affiliation":[{"name":"University of Washington\/Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7593","authenticated-orcid":false,"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Washington\/Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-0176","authenticated-orcid":false,"given":"Ann","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"issue":"9323","key":"2021031815154487200_B1","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"8852","key":"2021031815154487200_B2","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"6","key":"2021031815154487200_B3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/bjh.12824","article-title":"F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"165","author":"Gentzler","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"2021031815154487200_B4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hon.2014","article-title":"High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors","volume":"31","author":"Cocorocchio","year":"2013","journal-title":"Hematol Oncol"},{"issue":"3","key":"2021031815154487200_B5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"2021031815154487200_B6","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2021031815154487200_B7","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/bmt.2013.88","article-title":"Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin\u2019s lymphoma: outcome after high-dose chemotherapy and auto-SCT","volume":"48","author":"Akhtar","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2021031815154487200_B8","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00277-011-1209-0","article-title":"Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival","volume":"90","author":"Sucak","year":"2011","journal-title":"Ann Hematol"},{"issue":"9","key":"2021031815154487200_B9","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3109\/10428194.2011.573889","article-title":"Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma","volume":"52","author":"Mocikova","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2021031815154487200_B10","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/cncr.22714","article-title":"Pretransplant positive positron emission tomography\/gallium scans predict poor outcome in patients with recurrent\/refractory Hodgkin lymphoma","volume":"109","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"2021031815154487200_B11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2005-11-006957","article-title":"Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma","volume":"109","author":"Schot","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2021031815154487200_B12","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","article-title":"Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin\u2019s lymphoma responding to prior salvage therapy","volume":"97","author":"Devillier","year":"2012","journal-title":"Haematologica"},{"issue":"12","key":"2021031815154487200_B13","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bbmt.2013.09.018","article-title":"Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma","volume":"19","author":"Hahn","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2021031815154487200_B14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.bmt.1704483","article-title":"Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin\u2019s lymphoma","volume":"33","author":"Popat","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2021031815154487200_B15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma","volume":"12","author":"Majhail","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2021031815154487200_B16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2012.10.029","article-title":"Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin\u2019s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome","volume":"19","author":"Nieto","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2021031815154487200_B17","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2001.19.5.1395","article-title":"Autologous stem-cell transplantation for Hodgkin\u2019s disease: results and prognostic factors in 494 patients from the Grupo Espa\u00f1ol de Linfomas\/Transplante Aut\u00f3logo de M\u00e9dula Osea Spanish Cooperative Group","volume":"19","author":"Sureda","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021031815154487200_B18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3324\/haematol.2011.047670","article-title":"Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin\u2019s lymphoma resistant to platinum-containing first-line salvage chemotherapy","volume":"97","author":"Villa","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"2021031815154487200_B19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"2021031815154487200_B20","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial [published correction appears in J Clin Oncol. 2018;36(26):2748]","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"31","key":"2021031815154487200_B21","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"2021031815154487200_B22","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2021031815154487200_B23","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ajh.25154","article-title":"Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers","volume":"93","author":"Rossi","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"2021031815154487200_B24","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1634\/theoncologist.2020-0167","article-title":"Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy","volume":"25","author":"Carreau","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"2021031815154487200_B25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bjh.16756","article-title":"Checkpoint blockade treatment sensitises relapsed\/refractory non-Hodgkin lymphoma to subsequent therapy","volume":"191","author":"Carreau","year":"2020","journal-title":"Br J Haematol"},{"key":"2021031815154487200_B26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","article-title":"Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"112","author":"Schvartsman","year":"2017","journal-title":"Lung Cancer"},{"issue":"4","key":"2021031815154487200_B27","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jtho.2017.11.113","article-title":"Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer","volume":"13","author":"Costantini","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"9","key":"2021031815154487200_B28","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.21873\/anticanres.13688","article-title":"Previous immune checkpoint inhibitor treatment to increase the efficacy of docetaxel and ramucirumab combination chemotherapy","volume":"39","author":"Harada","year":"2019","journal-title":"Anticancer Res"},{"issue":"4","key":"2021031815154487200_B29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/1759-7714.12998","article-title":"Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients","volume":"10","author":"Shiono","year":"2019","journal-title":"Thorac Cancer"},{"issue":"3","key":"2021031815154487200_B30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00262-012-1390-6","article-title":"Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer","volume":"62","author":"Ramakrishnan","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2021031815154487200_B31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2021031815154487200_B32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"issue":"27","key":"2021031815154487200_B33","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"25","key":"2021031815154487200_B34","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2021031815154487200_B35","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/annonc\/mdu387","article-title":"Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"25","author":"Gerrie","year":"2014","journal-title":"Ann Oncol"},{"key":"2021031815154487200_B36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2019-122576","article-title":"Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: long-term follow-up results from the single-arm phase 1\/2 study","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"issue":"21","key":"2021031815154487200_B37","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2021031815154487200_B38","doi-asserted-by":"crossref","first-page":"e993","DOI":"10.1634\/theoncologist.2020-0040","article-title":"Impact of treatment beyond progression with immune checkpoint blockade in Hodgkin lymphoma","volume":"25","author":"Merryman","year":"2020","journal-title":"Oncologist"},{"issue":"23","key":"2021031815154487200_B39","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021031815154487200_B40","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood-2019-122171","article-title":"Risk of relapse after Anti-PD1 discontinuation and efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma","volume":"134","author":"Manson","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2021031815154487200_B41","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2021031815154487200_B42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2015.332","article-title":"Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis","volume":"51","author":"Rashidi","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"30","key":"2021031815154487200_B43","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","article-title":"Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2021031815154487200_B44","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2021031815154487200_B45","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2021031815154487200_B46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil","volume":"132","author":"Herbaux","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2021031815154487200_B47","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/6\/1648\/1803391\/advancesadv2020003556.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/6\/1648\/1803391\/advancesadv2020003556.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T11:16:24Z","timestamp":1616066184000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/6\/1648\/475467\/Autologous-stem-cell-transplantation-after-anti-PD"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003556","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]}}}